株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

小分子標的癌治療の世界市場

Small-Molecule Targeted Cancer Therapies: World Market 2013-2023

発行 Visiongain Ltd 商品コード 226942
出版日 ページ情報 英文 174 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=148.54円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
小分子標的癌治療の世界市場 Small-Molecule Targeted Cancer Therapies: World Market 2013-2023
出版日: 2012年12月10日 ページ情報: 英文 174 Pages
概要

当レポートでは、小分子標的癌治療の世界市場に注目し、収益性を予測すべく、同分野の動向や発展の機会を探るなか、現在癌治療の第一線に位置する商品、製薬企業、また先進国市場を具体検証する一方、製薬産業の変化が小分子治療法にもたらす影響ほか市場展開についての最新情報を集め、概略以下の構成でお届けします。

第1章 エグゼクティブサマリー

  • 所見の概要
  • レポートの範囲と形式
  • 調査・分析方法

第2章 イントロダクション:癌 - その生理学、苦しみ、治療

  • 標的癌治療
  • 癌の生理学
    • 制御不能な成長
    • 脱分化
    • 侵襲性と転移
    • 癌の原因
  • 癌の発症および死亡率
    • 発症率
    • 死亡率
    • 生存率
  • 腫瘍の治療
    • 化学療法
    • 従来の抗悪性腫瘍剤
    • 新しい抗悪性腫瘍剤
      • キナーゼ受容体拮抗薬
      • その他の新抗悪性腫瘍剤
    • ホルモン療法
    • 能動免疫療法
    • 受動免疫療法:モノクローナル抗体
  • 小分子標的癌治療
    • シグナル伝達阻害剤
    • 遺伝子発現ほか細胞機能の調整剤
    • 小分子アポトーシス誘導剤
    • 血管形成阻害剤
  • 標的癌治療:小分子薬

第3章 小分子癌標的治療市場

  • 小分子標的癌治療世界市場
  • 成長しつつある小分子癌治療市場
    • 小分子癌治療市場の売上予測
  • 小分子癌治療市場第一線にある製品

第4章 小分子癌治療市場:先進各国市場

  • 米国
  • 日本
  • 欧州先進国
  • 新興経済
  • 中国
  • インド
  • 市場予測サマリー

第5章 第一線にある小分子抗癌剤製品

  • グリベック(Glivec/Gleevec)- 製薬企業:Novartis
    • 売上
    • 売上予測
    • タシグナ(Tasigna)への切り替え
  • レブラミド(Revlimid)- 製薬企業:Celgene
    • 売上
    • 二次的悪性腫瘍
    • 売上予測
  • アリムタ (Alimta)- 製薬企業:Eli Lilly
    • 売上
    • 特許論争
    • 売上予測
  • ベルケード(Velcade)- 製薬企業:武田薬品/Johnson & Johnson
    • 売上
    • 最近の開発製品
    • 売上予測
  • タルセバ(Tarceva)- 製薬企業:Roche
    • 売上
    • 特許失効
    • 売上予測
  • タキソテール(Taxotere)- 製薬企業:Sanofi
    • 売上
    • 特許失効
    • 売上予測
  • スーテント(Sutent)- 製薬企業:Pfizer
    • 売上
    • ジェネリック製品のチャレンジ
    • 売上予測
    • 追加効能承認
    • 追加用途および投与剤形に対しての後期臨床試験
  • ネクサバール(Nexavar)- 製薬企業:Bayer/Onyx
    • 売上
    • 特許失効
    • 売上予測
  • スプリセル(Sprycel)- 製薬企業:Bristol-Myers Squibb
    • 売上
    • 特許失効
    • 売上予測
  • アリミデックス(Arimidex)- 製薬企業:AstraZeneca
    • 売上
    • 特許失効
    • 売上予測

第6章 小分子癌治療製品のR&Dパイプライン

  • 概要
  • 小分子肺癌パイプライン製品
    • アファチニブ (Afatinib) - 製薬企業:Boehringer Ingelheim
    • クリゾチニブ(Crizotinib)/Xalkori - 製薬企業:Pfizer
  • 小分子乳癌パイプライン製品
    • 製品ライン拡張
    • ハラベン(Halaven)- 製薬企業:エーザイ
  • 小分子結腸直腸癌パイプライン製品
    • Regorafenib/BAY73-4506 - 製薬企業:Bayer
    • Perifosine/KRX 0401 - 製薬企業:Keryx/Aeterna Zentaris
  • 小分子胃癌パイプライン製品
    • 製品ライン拡張
    • テラチニブ(Telatinib)- 製薬企業:ACT Biotech
  • 小分子前立腺癌パイプライン製品
    • MDV 3100 - 製薬企業:Astellas/Medivation
    • CB7630 - 製薬企業:Centocor Ortho Biotech
  • 小分子多発性骨髄腫パイプライン製品
    • プロテアソーム阻害薬:次世代
    • 免疫調節剤:骨髄腫治療にとって過去か未来か
    • ヒストンデアセチラーゼ阻害剤:重要な新領域
    • キナーゼ阻害剤・シグナル伝達阻害薬:最大のパイプライン領域
    • 熱ショックタンパク質誘導剤
    • アポトーシス誘導剤:4製品が第二段階に
    • その他の骨髄腫治療製品
  • 小分子遺伝子外治療パイプライン製品
    • ヒストン脱アセチル化酵素(HDAC)阻害薬
    • DNMT阻害薬

第7章 小分子癌治療市場の定量分析

  • 小分子癌治療市場のSWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • バイオシミラーおよびジェネリック薬:機会か脅威か
  • オーダーメード医療と癌

第8章 面談調査

  • EpiTherapeutics社CEO、Dr Martin Bonde
  • Syndax Pharmaceuticals社CEO兼社長、Dr Joanna Horobin

第9章 結論

  • 将来有望な小分子癌治療市場
  • 小分子癌治療市場の第一線製品
  • 世界最大の小分子癌治療市場に留まる米国
  • 国内市場成長率ではインドと中国が最速成長市場に
  • 多種多様な癌に手堅く対応するR&Dパイプライン
  • 結びの言葉

図表一覧

企業索引

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Cancer treatment with small molecules - your guide to trends and revenue prospects

What does the future hold for small targeted agents to treat cancers? Visiongain's updated report gives you revenue predictions to 2023. There you find sales data, R&D trends, opportunities and commercial prospects.

You see the potential of those molecularly-targeted technologies and products. Our new analysis lets you assess forecasted sales at overall world market, product and national level. Discover how and why revenues can increase.


Forecasts and other analyses to help you find the best growth opportunities

In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You gain 72 tables, 34 charts and four research interviews.

You can stay ahead in knowledge, benefiting your research and analyses. Much scope remains for medicines to combat growth, progression and spread of tumours (tumors). Our work lets you investigate the most promising areas of that drug industry and market.

The following sections show what you discover in our report.

You see prospects for the world market and top products

Along with predictions of overall world market value, you see revenue forecasts for 10 leading brands at world level. You find data from 2011 to 2023 for these products:

  • Glivec (Gleevec)
  • Revlimid
  • Alimta
  • Velcade
  • Tarceva
  • Taxotere
  • Sutent
  • Nexavar
  • Sprycel
  • Arimidex.

You find analysis of competition, as well as commercial drivers and restraints. Discover the potential of those targeted applications of oncology.

Our work also breaks the overall world forecast into prominent national markets.

What are the prospects in leading countries?

There are many opportunities in developed and developing countries, our report explains.

You discover individual revenue forecasts to 2023 for nine national markets, seeing relevant overall sales:

  • US
  • Japan
  • Germany, France, UK, Italy and Spain (EU5)
  • India and China.

See what's likely to happen. There will be strong growth in established markets and in developing countries, our analyses show. You find areas with highest potential.

China and India, in particular, will achieve high revenue growth. Other markets - including the US - will also expand fast. Launch of new products will stimulate growth worldwide.

What about the oncology R&D pipeline for those drugs?

You see developmental trends for treating many cancers (lung, breast, colorectal, stomach, multiple myeloma and prostate, among others):

  • Kinase inhibitors and signal transduction blockers
  • VEGF agents and androgen receptor antagonism
  • Signal transduction blocking and proteasome inhibition candidates
  • Immunomodulators, aurora kinase inhibiting and peptide prodrugs
  • Gene expression, epigenetic treatments and cellular function regulators
  • E-selectin antagonists and histone deacetylase inhibitors.

Our work also discusses these technologies and others, including pharmacogenomics:

  • Mitosis inhibitors and apoptosis inducers
  • HDAC mechanisms and other drug targets
  • Heat shock protein (HSP) modulators
  • Hormones and angiogenesis blockers
  • Transcription factor regulators and siRNA processes and products
  • Biomarkers, genome screening and molecular diagnostics (inc. theranostics).

R&D pipelines for targeted therapies are vast and strong. Discover progress for injectable and oral medicines, including antineoplastics. Also, you see outlooks for treating solid tumours and other forms. You gain insight into developments and their significance.

Emerging technology holds great promise. Many opportunities exist for large companies and specialty pharma firms, allowing market expansion from 2013.

Leading companies and market value in 2016

Overall world revenue for that market area will reach $32.7bn in 2016, our report forecasts. We predict strong revenue growth to 2023, owing to rising demand for anti-cancer medicines. Rising disease incidence and prevalence will stimulate market growth.

In our study you find discussions of Novartis, Eli Lilly, Roche, Pfizer, Takeda and many other developers and manufacturers. You find outlooks for revenue growth.

This decade, many opportunities will arise for pharmaceutical and biotechnology companies in targeted cancer treatment. Our work shows you the commercial possibilities.

Nine ways Small-Molecule Targeted Cancer Therapies: World Market 2013-2023 helps you

To sum up, our investigation gives you the following knowledge on the topic:

  • Forecasted revenues to 2023 for the overall world market - you discover the industry's future prospects
  • Predicted revenues of 10 leading products to 2023 - you analyse crucial developments for top brands
  • Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, India and China - you see national sales outlooks
  • Review of R&D pipelines by treatment area and technology - you hear about progress in established and emerging research areas
  • Assessment of companies - you find activities, products, strategies and outlooks
  • Opinions on the sector - you discover our interviews with authorities in the field
  • Competition and opportunities influencing sales - you see what affects the future
  • Discussions of what stimulates and restrains the industry and market - you assess business trends, drivers and restraints
  • Prospects for established firms and specialists seeking to enter the sector - you see factors and outlooks for success.

You gain information found nowhere else

That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative.

With our report you are less likely to fall behind in knowledge or miss opportunity. Discover how our work could benefit your research, analyses and decisions, saving you time and getting you recognition for commercial insight.

Table of Contents

1. Executive Summary

  • 1.1 Overview of Findings
  • 1.2 Scope and Format of the Report
  • 1.3 Research and Analysis Methods

2. Introduction: Cancer, its Physiology, Burden and Treatment

  • 2.1 Targeted Cancer Therapies
  • 2.2 The Physiology of Cancer
    • 2.2.1 Uncontrolled Growth
    • 2.2.2 Dedifferentiation
    • 2.2.3 Invasiveness and Metastasis
    • 2.2.4 Causes of Cancer
  • 2.3 Incidence and Mortality for Cancer
    • 2.3.1 Incidence
    • 2.3.2 Mortality
    • 2.3.3 Survival
      • 2.3.3.1 The Developed World
      • 2.3.3.2 The Developing World
  • 2.4 Treating Tumours
    • 2.4.1 Chemotherapy
    • 2.4.2 Traditional Antineoplastics
    • 2.4.3 Novel Antineoplastics
      • 2.4.3.1 Kinase Receptor Antagonists
      • 2.4.3.2 Other Novel Antineoplastics
    • 2.4.4 Hormone Therapies
    • 2.4.5 Active Immunotherapy
    • 2.4.6 Passive Immunotherapy: Monoclonal Antibodies
  • 2.5 Small-Molecule Targeted Cancer Therapies
    • 2.5.1 Signal Transduction Inhibitors
    • 2.5.2 Gene Expression and Other Cellular Function Regulators
    • 2.5.3 Small-Molecule Apoptotic Inducing Drugs
    • 2.5.4 Angiogenesis Blockers
  • 2.6 Targeted Cancer Therapies: Small-Molecule Drugs

3. The Small-Molecule Cancer Therapies Market, 2013-2023

  • 3.1 The World Small-Molecule Cancer Therapies Market in 2011
  • 3.2 Growing Market for Small-Molecule Cancer Therapies
    • 3.2.1 Sales Forecast for Small-Molecule Cancer Therapies, 2012-2016
    • 3.2.2 Sales Forecast for Small-Molecule Cancer Therapies, 2017-2023
  • 3.3 Leading Products in the Small-Molecule Cancer Therapies Market

4. Small-Molecule Cancer Therapies: Leading National Markets, 2013-2023

  • 4.1 The US Small-Molecule Cancer Therapies Market, 2012-2023
  • 4.2 The Japanese Small-Molecule Cancer Therapies Market, 2012-2023
  • 4.3 The Leading European Small-Molecule Cancer Therapies Markets, 2012-2023
  • 4.4 Emerging-Economy Small-Molecule Cancer Therapies Markets
  • 4.5 The Chinese Small-Molecule Cancer Therapies Market, 2012-2023
  • 4.6 The Indian Small-Molecule Cancer Therapies Market, 2012-2023
  • 4.7 Summary of Market Forecasts

5. Leading Small-Molecule Anti-Cancer Products, 2013-2023

  • 5.1 Glivec/Gleevec (Novartis)
    • 5.1.1 Glivec/Gleevec Sales 2011
    • 5.1.2 Glivec/Gleevec Sales Forecast, 2012-2016
    • 5.1.3 Glivec/Gleevec Sales Forecast, 2017-2023
    • 5.1.4 Tasigna Set to Replace Glivec/Gleevec
  • 5.2 Revlimid (Celgene)
    • 5.2.1 Revlimid Sales 2011
    • 5.2.2 Secondary Malignancies
    • 5.2.3 Revlimid Sales Forecast, 2012-2016
    • 5.2.4 Revlimid Sales Forecast, 2017-2023
  • 5.3 Alimta (Eli Lilly)
    • 5.3.1 Alimta Sales 2011
    • 5.3.2 Patent Disputes
    • 5.3.3 Alimta Sales Forecast, 2012-2016
    • 5.3.4 Alimta Sales Forecast, 2017-2023
  • 5.4 Velcade (Takeda/J&J)
    • 5.4.1 Velcade Sales 2011
    • 5.4.2 Recent Developments
    • 5.4.3 Velcade Sales Forecast, 2012-2016
    • 5.4.4 Velcade Sales Forecast, 2017-2023
  • 5.5 Tarceva (Roche)
    • 5.5.1 Tarceva Sales 2011
    • 5.5.2 Patent Expiry
    • 5.5.3 Tarceva Sales Forecast, 2012-2016
    • 5.5.4 Tarceva Sales Forecast, 2017-2023
  • 5.6 Taxotere (Sanofi)
    • 5.6.1 Taxotere Sales 2011
    • 5.6.2 Patent Expiry
    • 5.6.3 Taxotere Sales Forecast, 2012-2016
    • 5.6.4 Taxotere Sales Forecast, 2017-2023
  • 5.7 Sutent (Pfizer)
    • 5.7.1 Sutent Sales 2011
    • 5.7.2 Generics Challenges
    • 5.7.3 Sutent Sales Forecast, 2012-2016
    • 5.7.4 Sutent Sales Forecast, 2017-2023
    • 5.7.5 Additional Indication Approval.
    • 5.7.6 Late-Stage Clinical Trials for Additional Uses and Dosage Forms for Sutent
  • 5.8 Nexavar (Bayer/Onyx)
    • 5.8.1 Nexavar Sales 2011
    • 5.8.2 Patent Expiry
    • 5.8.3 Nexavar Sales Forecast, 2012-2016
    • 5.8.4 Nexavar Sales Forecast, 2017-2023
  • 5.9 Sprycel (Bristol-Myers Squibb)
    • 5.9.1 Sprycel Sales 2011
    • 5.9.2 Patent Expiry
    • 5.9.3 Sprycel Sales Forecast, 2012-2016
    • 5.9.4 Sprycel Sales Forecast, 2017-2023
  • 5.10 Arimidex (AstraZeneca)
    • 5.10.1 Arimidex Sales 2011
    • 5.10.2 Patent Expiry
    • 5.10.3 Arimidex Sales Forecast, 2012-2016
    • 5.10.4 Arimidex Sales Forecast, 2017-2023

6. R&D Pipeline for Small-Molecule Cancer Products

  • 6.1 Overview
  • 6.2 Small-Molecule Lung Cancer Pipeline 2012
    • 6.2.1 Afatinib (Boehringer Ingelheim), a Second-generation Tyrosine Kinase Inhibitor
    • 6.2.2 Crizotinib/Xalkori (Pfizer) Receives FDA Approval
  • 6.3 Small-Molecule Breast Cancer Pipeline 2012
    • 6.3.1 Line Extensions
    • 6.3.2 Halaven (Eisai) Enters Phase III for Non-Small Cell Lung cancer
  • 6.4 Small-Molecule Colorectal Cancer Pipeline 2012
    • 6.4.1 Regorafenib/BAY73-4506 (Bayer), a Promising Candidate Targeting Multiple Pathways including VEGF
    • 6.4.2 Perifosine/KRX 0401 (Keryx/Aeterna Zentaris), Oral P13K Inhibitor Granted Fast Track Status by FDA
  • 6.5 Small-Molecule Stomach Cancer Pipeline 2012
    • 6.5.1 Line Extensions
    • 6.5.2 Telatinib, ACT Biotech's Lead Anti-angiogenic Pipeline Product
  • 6.6 Small-Molecule Prostate Cancer Pipeline 2012
    • 6.6.1 MDV 3100 (Astellas/Medivation), an Oral Androgen Receptor Antagonist
    • 6.6.2 CB7630 (Centocor Ortho Biotech) Formulated as a Prodrug for Prostrate Cancer
  • 6.7. Small-Molecule Multiple Myeloma Pipeline, 2012
    • 6.7.1 Proteasome Inhibitors: the Next Generation
      • 6.7.1.1 CEP 18770 (Cephalon) - Late-phase Trials for Relapsed/Refractory Multiple Myeloma
      • 6.7.1.2 Marizomib (Nereus) Shows Promising Results in Early-phase Trials
      • 6.7.1.3 MLN 9708 (Takeda), First Oral Proteosome Inhibitor to Reach Clinical Trials
      • 6.7.1.4 CEP 28331 (Cephalon), Another Proteosome Inhibitor in Development
    • 6.7.2 Immunomodulators: The Past or the Future for Myeloma Treatment?
      • 6.7.2.1 Afinitor (Novartis) Shows Positive Data for Myeloma in Early-stage Trials
      • 6.7.2.2 E-Selectin Antagonists (GlycoMimetics)
    • 6.7.3 Histone Deacetylase Inhibitors: An Important Field
      • 6.7.3.1 Istodax (Celgene Corporation) in Late-phase Trials for Myeloma and T-cell Lymphoma
      • 6.7.3.2 Zolinza (Merck & Co.) in Late-phase Development for Mesothelioma and Other Indications
      • 6.7.3.3 AR 42 (Arno), a Histone Deacetylase Inhibitor Showing Early Promise
      • 6.7.3.4 Givinostat (Italfarmaco) in Trials for Relapsed/Refractory Multiple Myeloma Patients
      • 6.7.3.5 HDAC6 Inhibitors (Acetylon) Targeting Multiple Myeloma
    • 6.7.4 Kinase Inhibitors/Signal Transduction Blockers: The Largest Pipeline Sector
      • 6.7.4.1 Votrient (GlaxoSmithKline): Late-phase Development for Ovarian, Breast and Soft Tissue Sarcoma
      • 6.7.4.2 Lenocta (VioQuest), a Promising Tyrosine Phosphatise Inhibitor
      • 6.7.4.3 Ruxolitnib (Novartis) in Late-phase Trials for Multiple Indications
      • 6.7.4.4 Lestaurtnib (Cephalon), a Tyrosine Kinase Inhibitor Reaches Phase III for Myeloma and Prostrate Cancer
      • 6.7.4.5 Masitnib (AB Science) in Late-phase Trials for a Range of Cancer Indications
      • 6.7.4.6 AT 9283 (Astex Therapeutics), a JAK-2 & Mitosis Inhibitor in Multiple Trials
      • 6.7.4.7 Dovitnib (Novartis) Begins Phase II Testing for Myeloma and Other Indications
      • 6.7.4.8 P276 (Piramal Life Sciences) CDK1/4 Inhibitor Targeting Multiple Indications
      • 6.7.4.9 PD332991 (Pfizer) Enters Late-phase Development for Multiple Indications
      • 6.7.4.10 ENMD 2076 (EntreMed) Receives Orphan Drug Status in the US
      • 6.7.4.11 AT 7519 (Astex Therapeutics), an Injectable CDK Inhibitor with Promise in Mono and Combination Therapy
      • 6.7.4.12 MLN 8237 (Takeda), a Promising Oral Bioavailable Drug in Trials for Multiple Indications
      • 6.7.4.13 Estybon (Onconova) in Development for Multiple Cancer Indications
      • 6.7.4.14 CX 4945 (Cylene), a CK2 Inhibitor in Early Development
      • 6.7.4.15 GDC 0941 (Roche), a Promising Candidate in Early-phase Trials for Multiple Indications
      • 6.7.4.16 INK 128 (Intellikine): Targeting TORC1/2 Pathway
      • 6.7.4.17 SF 1126 (Semafore), an Injectable Peptide Prodrug Targeting PI 3-Kinase Pathway
      • 6.7.4.18 SNS 032 (Sunesis/Bristol-Myers Squibb) in Early Development for Multiple Indications
      • 6.7.4.19 Sprycel (Otsuka/Bristol-Myers Squibb): Abl/Src Tyrosine Tinase Inhibitor in Multiple Trials
      • 6.7.4.20 TG 02 (Tragara/S*BIO) in Trials for Relapsed/Refractory Myeloma
      • 6.7.4.21 R763 (Rigel), an Aurora Kinase Inhibitor with Anti-Myeloma Promise
    • 6.7.5 Heat Shock Protein (HSP) Modulators
      • 6.7.5.1 AUY 922 (Novartis) in Early Trials for Solid Tumour and Myeloma
      • 6.7.5.2 KW 2478 (Kyowa Hakko Kirin), a HSP90 Inhibitor intended for Non-Hodgkin's Lymphoma and Other Indications
      • 6.7.5.3 NVP BEP800 (Novartis): HSP90 Inhibitor with Early Promise
    • 6.7.6 Apoptosis Inducers: Four Products at Phase II
      • 6.7.6.1 GCS 100 (Prospect Therapeutics) in Late-stage Development for Multiple Indications
      • 6.7.6.2 Amplimexon (AmpliMed) - US Orphan Drug Designation for Several Indications
      • 6.7.6.3 Trisenox (Nippon Shinyaku), a Promising Apoptotic with Unknown Mechanism
      • 6.7.6.4 Noscapine (Cougar Biotechnology), an Orally Active Alkaloid Showing Early Promise
      • 6.7.6.5 BMS 833923 (Bristol-Myers Squibb): Targets Hedgehog Pathway
      • 6.7.6.6 SNS 01-T (Senesco): siRNA Product Designated US Orphan Drug Status
    • 6.7.7 Other Small-Molecule Myeloma Products
      • 6.7.7.1 Products in Phase II
      • 6.7.7.2 Amnolake (CytRx) in Late-stage Development for Multiple Indications
      • 6.7.7.3 Coprexa TM (Attenuon) in Phase II Trials
      • 6.7.7.4 Brostallacin (Cell Therapeutics), a Potential Chemotherapy Agent
      • 6.7.7.5 CYT 997 (YM BioSciences) in Late-phase Development in Australia
      • 6.7.7.6 ARRY 520 (Array BioPharma), a Promising Injectable for AML and Myeloma
      • 6.7.7.7 Zinapar (Ziopharm) in Development for Multiple Indications
      • 6.7.7.8 Products in Phase I
      • 6.7.7.9 Quadramet (EUSA Pharma) in Late-stage Trials for Metastasis and Prostate Cancer
      • 6.7.7.10 LC1 (Leuchemix): Orally-bioavailable Parthenolide Analogue
      • 6.7.7.11 MLN 4924 (Takeda): Targets Multiple Oncology Indications
      • 6.7.7.12 OPB 31121 (Otsuka), a Transcription Factor Regulator/STAT Inhibitor in Early-Phase Development
      • 6.7.7.13 Zalypsis (PharmaMar), an Injectable Candidate for Lymphoma and Solid Tumours
      • 6.7.7.14 Products in Preclinical Studies
      • 6.7.7.15 INNO 206 (CytRx), Showing Early Promise in Myeloma
      • 6.7.7.16 Ostabolin-C (Zelos), a Parathyroid Hormone Analogue with Potential in Myeloma Treatment
      • 6.7.7.17 IRE1-alfa inhibitor (Mannkind), First-in-class Candidate Targeting Novel Pathways
      • 6.7.7.18 HIF Signalling Inhibitors (Elara)
      • 6.7.7.19 PS 031291 (Ligand), Promising Chemokine Receptor 1 (CCR1) Antagonist
      • 6.7.7.20 SST 0001 (Sigma-Tau), Aimed at bFGF Growth Factors
      • 6.7.7.21 CGEN 928 (Compugen), Targeting Multiple Myeloma
      • 6.7.7.22 Ubiquitin-Specific Peptidase 7 (USP7) Inhibitors by Progenra
  • 6.8 Small-Molecule Epigenetic Therapy Pipeline, 2012
    • 6.8.1 HDAC Inhibitors
      • 6.8.1.1 PXD-101 (Belinostat, TopoTarget/Spectrum Pharmaceuticals)
      • 6.8.1.2 LBH589 (Panobinostat, Novartis), Gains Orphan Drug Status for Hodgkin's Lymphoma
      • 6.8.1.3 Entinostat (Syndax Pharmaceuticals), Targeting Breast and Lung Indications
      • 6.8.1.4 4SC-201 (Resminostat, 4SC), Oral Pan-HDAC Inhibitor in Development for Variety of Cancers
      • 6.8.1.5 MGCD-0103 (Mocetinostat, MethylGene), Targeting Class I/IV Histone Deacetylases
      • 6.8.1.6 SB939 (S*BIO), First Anti-cancer Therapy Developed in Singapore
      • 6.8.1.7 ACY-1215, Acetylon Pharmaceuticals' Second Generation HDAC Inhibitor for Multiple Myeloma
      • 6.8.1.8 Valproic Acid, an Epilepsy Drug in Multiple Trials for Cancer Indications
    • 6.8.2 DNMT Inhibitors
      • 6.8.2.1 SGI-110, Astex Pharmaceuticals' Second Generation DNMT Inhibitor
      • 6.8.2.2 CP-4200 (Clavis Pharma) - Showing Early-stage Promise

7. Qualitative Analysis of the Small-Molecule Cancer Therapies Market, 2013-2023

  • 7.1 SWOT Chart for Small-Molecule Cancer Therapies Market 2013-2023
  • 7.2 Strengths
    • 7.2.1 Cancer Treatment has Proven Commercial Potential
    • 7.2.2 High Profile Nature of Cancer
    • 7.2.3 Off-Label Prescriptions are Common
    • 7.2.4 Strong Drug Development Incentives
  • 7.3 Weaknesses
    • 7.3.1 Tumours and Multidrug Resistance (MDR)
    • 7.3.2 Pricing-Out the Developing World?
  • 7.4 Opportunities
    • 7.4.1 Cancer is a Key Business Area for the Pharmaceutical Industry
    • 7.4.2 Rising Incidence of Cancer
      • 7.4.1.1 Aging Populations
      • 7.4.1.2 Smoking
      • 7.4.1.3 Obesity
      • 7.4.1.4 The Developing World
    • 7.4.3 Greater Understanding of Cancer Gives Opportunities in the Cancer Treatment Industry
    • 7.4.4 Advanced Diagnostics with Pharmacogenomics: Impact on Cancer Therapies
    • 7.4.5 Live Licensing and In-Life Testing
    • 7.4.6 Convenience of Targeted Drugs versus Chemotherapy
  • 7.5 Threats
    • 7.5.1 Healthcare Spending Restraints Threaten Cancer Drug Revenues
    • 7.5.2 The Cost-Effectiveness Debate
    • 7.5.3 Governments are a Leading Payer for Drugs
    • 7.5.4 Efficacy, Toxicity and Alternative Treatments
  • 7.6 Biosimilars and Generics: Opportunity or Threat?
  • 7.7 Personalised Medicine and Cancer
    • 7.7.1 Biomarkers and Diagnostics
    • 7.7.2 Small-Molecule (Metabolic) Biomarkers
    • 7.7.3 Cancer Heterogeneity
    • 7.7.4 Pharmacogenomics
    • 7.7.5 Genome Screening
    • 7.7.6 Theranostics

8. Research Interviews

  • 8.1 Dr Martin Bonde, CEO, EpiTherapeutics
    • 8.1.1 Potential for Histone Methyltransferase Inhibitors
    • 8.1.2 Future of Epigenetics Research
    • 8.1.3 Histone Methyltransferase Inhibitors on Market within Decade?
    • 8.1.4 Challenges in Developing Epigenetic Therapies
    • 8.1.5 Benefits of University Spin-Outs
  • 8.2 Dr Joanna Horobin, President and CEO, Syndax Pharmaceuticals
    • 8.2.1 On Challenges Facing Cancer Therapies
    • 8.2.2 On Selective Targeting of Therapies
    • 8.2.3 On Drug Resistance and Targeted Therapies
    • 8.2.4 On Drug Resistance and Market Opportunity
    • 8.2.5 On Entinostat, Lung and Breast Cancer Therapies
  • 8.3 Interview with an External Authority (Views Given Anonymously)
    • 8.3.1 Obesity is a Strong Risk Factor for Cancer
    • 8.3.2 Multiple Myeloma Treatment: Proactive versus Reactive
    • 8.3.3 Treatment Options for Obese Patients
    • 8.3.4 Multiple Myeloma Incidence Will Increase Due To Obesity
  • 8.4 Interview with Dr Kent C. Osborne, Baylor College of Medicine
    • 8.4.1 On Challenges in Developing Anti-Cancer Therapies
    • 8.4.2 On Major Areas of Focus
    • 8.4.3 On Cancer Vaccines
    • 8.4.4 On Areas with Potential for Increased Revenue Generation
    • 8.4.5 On R&D Pipeline
    • 8.4.6 On Difficulties Conducting Clinical Trials

9. Conclusions

  • 9.1 Small-Molecule Cancer Therapies Market Offers Promise
  • 9.2 Leading Products in Small-Molecule Cancer Therapies Market
  • 9.3 The US Will Remain the World's Largest Small-Molecule Cancer Therapies Market
  • 9.4 India and China Will be the Fastest-Growing National Markets
  • 9.5 R&D Pipelines for Many Cancer Types Are Strong
  • 9.6 Concluding Remarks

List of Tables

  • Table 2.1 Leading Causes of Death Worldwide, 2008 & 2015
  • Table 2.2 Most-Common Cancers by Incidence, 2008
  • Table 2.3 Most-Common Cancers by Mortality, 2008 & 2015
  • Table 2.4 Five-Year Survival Rates of Nine Cancers in the UK, 2009
  • Table 2.5 Categories of Anti-Cancer Drug, 2012
  • Table 2.6 Common Side-effects of Traditional Antineoplastic Chemotherapy
  • Table 2.7 Subcategories of TANs, 2012
  • Table 3.1 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2011-2016
  • Table 3.2 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2017-2023
  • Table 3.3 Small-Molecule Cancer Market: Top Ten Products - Sales and Market Shares, 2011, 2016 & 2023
  • Table 4.1 Leading Small-Molecule Cancer Therapies: National Market Forecasts, 2011-2023
  • Table 5.1 Glivec/Gleevec Sales for US and RoW, 2009-2011
  • Table 5.2 Glivec/Gleevec Sales Forecast, 2011-2016
  • Table 5.3 Glivec/Gleevec Sales Forecast, 2017-2023
  • Table 5.4 Glivec/Gleevec: Sales Drivers and Restraints, 2012-2023
  • Table 5.5 Revlimid Sales Forecast, 2011-2016
  • Table 5.6 Revlimid Sales Forecast, 2017-2023
  • Table 5.7 Revlimid: Sales Drivers and Restraints, 2012-2023
  • Table 5.8 Alimta Sales for US and RoW, 2009-2011
  • Table 5.9 Alimta Sales Forecast, 2011-2016
  • Table 5.10 Alimta Sales Forecast, 2017-2023
  • Table 5.11 Alimta: Sales Drivers and Restraints, 2012-2023
  • Table 5.12 Velcade Sales by Company, 2009-2011
  • Table 5.13 Velcade Sales Forecast, 2011-2016
  • Table 5.14 Velcade Sales Forecast, 2017-2023
  • Table 5.15 Velcade: Sales Drivers and Restraints, 2012-2023
  • Table 5.16 Tarceva Sales Forecast, 2011-2016
  • Table 5.17 Tarceva Sales Forecast, 2017-2023
  • Table 5.18 Tarceva: Sales Drivers and Restraints, 2012-2023
  • Table 5.19 Taxotere: Approved Indications, 2012
  • Table 5.20 Taxotere Sales by Region, 2009-2011
  • Table 5.21 Taxotere Sales Forecast, 2011-2016
  • Table 5.22 Taxotere Sales Forecast, 2017-2023
  • Table 5.23 Taxotere: Sales Drivers and Restraints, 2012-2023
  • Table 5.24 Sutent Sales Forecast, 2011-2016
  • Table 5.25 Sutent Sales Forecast, 2017-2023
  • Table 5.26 Sutent: Sales Drivers and Restraints, 2012-2023
  • Table 5.27 Nexavar Sales Forecast, 2011-2016
  • Table 5.28 Nexavar Sales Forecast, 2017-2023
  • Table 5.29 Nexavar: Sales Drivers and Restraints, 2012-2023
  • Table 5.30 Sprycel Sales for US and RoW, 2009-2011
  • Table 5.31 Sprycel Sales Forecast, 2011-2016
  • Table 5.32 Sprycel Sales Forecast, 2017-2023
  • Table 5.33 Sprycel: Sales Drivers and Restraints, 2012-2023
  • Table 5.34 Arimidex Sales for US and RoW, 2009-2011
  • Table 5.35 Arimidex Sales Forecast, 2011-2016
  • Table 5.36 Arimidex Sales Forecast, 2017-2023
  • Table 5.37 Arimidex: Sales Drivers and Restraints, 2012-2023
  • Table 6.1 Abbreviations Used in Chapter 6
  • Table 6.2 Selected Small-Molecule Lung Cancer Pipeline Candidates in Phase III, 2012
  • Table 6.3 Selected Small-Molecule Lung Cancer Pipeline Candidates in Phase II/III, 2012
  • Table 6.4 Selected Small-Molecule Breast Cancer Pipeline Candidates in Phase II & III, 2012
  • Table 6.5 Selected Small-Molecule Colorectal Cancer Pipeline Candidates in Phase II & III, 2012
  • Table 6.6 Selected Small-Molecule Stomach Cancer Pipeline Candidates in Phase II & III, 2012
  • Table 6.7 Selected Small-Molecule Prostate Cancer Pipeline Candidates in Phase II & III, 2012
  • Table 6.8 Small-Molecule Pipeline Products for Multiple Myeloma, 2012
  • Table 6.9 Small-Molecule Multiple Myeloma Pipeline: Proteasome Inhibitors, 2012
  • Table 6.10 Small-Molecule Multiple Myeloma Pipeline: Immunomodulators, 2012
  • Table 6.11 Small-Molecule Multiple Myeloma Pipeline: Histone Deacetylase Inhibitors, 2012
  • Table 6.12 Small-Molecule Multiple Myeloma Pipeline: Kinase Inhibitor/Signal Transduction Blockers, 2012
  • Table 6.13 Small-Molecule Multiple Myeloma Pipeline: Heat Shock Protein Modulators, 2012
  • Table 6.14 Small-Molecule Multiple Myeloma Pipeline: Apoptosis Inducers, 2012
  • Table 6.15 Other Small-Molecule Myeloma Products: Phase II Pipeline, 2012
  • Table 6.16 Other Small-Molecule Myeloma Products: Phase I Pipeline, 2012
  • Table 6.17 Other Small-Molecule Myeloma Products: Preclinical Pipeline, 2012
  • Table 6.18 Selected Small-Molecule HDAC Inhibitor Pipeline Candidates, 2012
  • Table 6.19 Ongoing Clinical Trials for PXD-101 (Belinostat), 2012
  • Table 7.1 STEP Analysis of World Small-Molecule Cancer Drugs Market, 2013-2023
  • Table 7.2 SWOT Analysis of World Small-Molecule Cancer Drugs Market: Strengths and Weaknesses, 2013-2023
  • Table 7.3 SWOT Analysis of World Small-Molecule Cancer Drugs Market: Opportunities and Threats, 2013-2023
  • Table 9.1 Small-Molecule Cancer Drug Market: Top Ten Products - Sales and Market Shares, 2011
  • Table 9.2 Small-Molecule Cancer Drugs Market by Country, 2011, 2016, 2020 & 2023

List of Figures

  • Figure 2.1 Leading Causes of Death Worldwide, 2008 & 2015
  • Figure 2.2 Most-Common Cancers by Incidence, 2008
  • Figure 2.3 Most-Common Cancers by Mortality, 2008
  • Figure 2.4 Most-Common Cancers by Mortality, 2015
  • Figure 2.5 Five-Year Survival Rates of Nine Cancers in the UK, 2009
  • Figure 3.1 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2011-2016
  • Figure 3.2 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2017-2023
  • Figure 3.3 Small-Molecule Cancer Therapies: Sales Shares for Leading Products, 2011
  • Figure 3.4 Small-Molecule Cancer Therapies: Sales Shares for Leading Products, 2016
  • Figure 3.5 Small-Molecule Cancer Therapies: Sales Shares for Leading Products, 2020
  • Figure 3.6 Small-Molecule Cancer Therapies: Sales Shares for Leading Products, 2023
  • Figure 4.1 Leading National Small-Molecule Cancer Therapies Market Forecasts, 2011-2023
  • Figure 4.2 National Small-Molecule Cancer Therapies Market Forecasts: Lower Range, 2011-2023
  • Figure 4.3 Small-Molecule Cancer Therapies: Leading National Markets, 2011
  • Figure 4.4 Small-Molecule Cancer Therapies: Leading National Markets, 2016
  • Figure 4.5 Small-Molecule Cancer Therapies: Leading National Markets, 2020
  • Figure 4.6 Small-Molecule Cancer Therapies: Leading National Markets, 2023
  • Figure 5.1 Glivec/Gleevec Sales for US and RoW, 2011
  • Figure 5.2 Glivec/Gleevec Sales Forecast, 2011-2023
  • Figure 5.3 Revlimid Sales Forecast, 2011-2023
  • Figure 5.4 Alimta Sales for US and RoW, 2011
  • Figure 5.5 Alimta Sales Forecast, 2011-2023
  • Figure 5.6 Velcade Sales by Company, 2011
  • Figure 5.7 Velcade Sales Forecast, 2011-2023
  • Figure 5.8 Tarceva Sales Forecast, 2011-2023
  • Figure 5.9 Taxotere Sales by Region, 2011
  • Figure 5.10 Taxotere Sales Forecast, 2011-2023
  • Figure 5.11 Sutent Sales Forecast, 2011-2023
  • Figure 5.12 Nexavar Sales Forecast, 2011-2023
  • Figure 5.13 Sprycel Sales for US and RoW, 2011
  • Figure 5.14 Sprycel Sales Forecast, 2011-2023
  • Figure 5.15 Arimidex Sales by Region, 2011
  • Figure 5.16 Arimidex Sales Forecast, 2011-2023
  • Figure 9.1 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2011, 2013, 2016, 2020 & 2023

Companies Listed

  • 4SC
  • AB Science
  • Abbott Laboratories
  • Abgenix
  • Abraxis BioScience
  • Acceleron
  • Acetylon Pharmaceuticals
  • ACT Biotech
  • Actavis
  • Active Biotech
  • Adeona (formerly Pipex)
  • AERES Biomedical
  • Aeterna Zentaris
  • Agennix
  • Alexion
  • Alza
  • Allos Therapeutics
  • Ambit Biosciences
  • American Society of Clinical Oncology (ASCO)
  • American Society of Hematology (ASH)
  • Amgen
  • AmpliMed
  • Anthrogenesis
  • Apexigen
  • Apotex
  • APP Pharmaceuticals (part of the Fresenius Kabi Group)
  • ARIAD Pharmaceuticals
  • Arizona University
  • Arno
  • ArQule
  • Array BioPharma
  • Ascenta Therapeutics
  • Astellas Pharma
  • Astex Pharmaceuticals
  • Astex Therapeutics
  • AstraZeneca
  • Attenuon
  • AVEO Pharmaceuticals
  • Barr Laboratories
  • Bayer Healthcare
  • Baylor College of Medicine
  • Biogen Idec
  • BioInvent
  • Bionovo
  • Biotech Research & Innovation Centre [Copenhagen, Denmark]
  • Biotest
  • BioWa
  • BiPar Sciences (a subsidiary of Sanofi)
  • Boehringer Ingelheim
  • Bristol-Myers Squibb (BMS)
  • British Biotech
  • BTG
  • Canadian National Research Council
  • Cancer Research Technology
  • Cancer Research UK
  • Cancer Science Institute of Singapore (CSI Singapore)
  • Celanese
  • Celgene
  • Cell Therapeutics
  • Centres for Disease Control and Prevention (US)
  • Centocor Ortho Biotech
  • Centocor Research & Development
  • Cephalon
  • Cetus Corporation
  • China's State Food and Drug Administration
  • Chiron
  • Choongwae
  • Cipla
  • Clavis Pharma
  • Cleveland Clinic
  • Columbia University
  • Compugen
  • Concordia Pharmaceuticals
  • Constellation Pharmaceuticals
  • Cougar Biotechnology
  • Crinos
  • CTI Technologies
  • CuraGen
  • CureVac
  • Cyclacel Pharmaceuticals
  • CyDex
  • Cylene
  • Cytogen
  • Cytokinetics
  • CytRx
  • Daiichi Sankyo
  • Dako
  • Dana Farber Cancer Institute
  • Dendreon
  • Dr. Reddy's Laboratories
  • Eisai
  • Elan
  • Elara Pharmaceuticals
  • Eleison Pharmaceuticals
  • Eli Lilly
  • Endocyte
  • EntreMed
  • EpiTherapeutics
  • Epizyme
  • European Medicines Agency (EMEA/EMA)
  • European Molecular Biology Laboratory (EMBL)
  • EUSA Pharma (formerly Cytogen)
  • Exelixis
  • Facet Biotech
  • Food and Drug Administration (US FDA)
  • Fresenius Kabi
  • Genentech (now part of Roche)
  • Generex Biotechnology
  • Genmab
  • Genta
  • Genzyme
  • Geron
  • GlaxoSmithKline (GSK)
  • Gloucester Pharmaceuticals
  • GlycoGenesys
  • GlycoMimetics
  • GPC Biotech
  • Greenwich Therapeutics
  • GTC Biotherapeutics
  • Handok
  • Harvard University
  • Hospira
  • Human Genome Sciences
  • IkerChem
  • ILEX Oncology
  • ImClone Systems (a subsidiary of Eli Lilly)
  • Immune System Therapeutics
  • ImmunoGen
  • Incyte
  • Infinity Pharmaceuticals
  • Innate Pharma
  • Intas Biopharmaceuticals
  • Intellikine
  • International Cancer Genome Consortium
  • International Myeloma Working Group
  • Introgen Therapeutics
  • Isis Pharmaceuticals
  • Italfarmaco
  • Janssen-Cilag
  • Johnson & Johnson (J&J)
  • Kadmon Pharmaceuticals
  • Kaken
  • Karyopharm Therapeutics
  • Keryx Biopharmaceuticals
  • Keyaku Zentaris
  • Kosan Biosciences
  • KTB Tumorforschungs
  • Kyowa Hakko Kirin
  • Les Laboratoires Servier
  • Leuchemix
  • Leukaemia and Lymphoma Society
  • Ligand
  • Lipomed
  • Lonza
  • Mannkind
  • Marlborough Research and Development
  • Marshall Edwards
  • MD Anderson Cancer Center
  • MedImmune
  • Medivation
  • Merck & Co.
  • Merck KGaA
  • Merck Serono (part of Merck KGaA)
  • MethylGene
  • Micromet
  • Millennium Pharmaceuticals (now part of Takeda)
  • MorphoSys
  • Mount Sinai Medical Center [US]
  • Multiple Myeloma Research Consortium
  • Multiple Myeloma Research Foundation
  • Mylan Pharmaceuticals
  • Natco Pharma
  • National Cancer Institute (NCI) [US]
  • National Cancer Institute (US)
  • National Health Service (NHS) [UK]
  • National Institute for Clinical Excellence (NICE) [UK]
  • National University Cancer Institute Singapore (NCIS)
  • NCIC Clinical Trials Group
  • Nektar Therapeutics
  • Nereus
  • Nerviano Medical Sciences
  • Nippon Shinyaku
  • Novartis
  • Novo Nordisk
  • Novogen
  • Ohio State University
  • OncoGenex Pharmaceuticals
  • Onconova
  • Oncova
  • Ono Pharmaceuticals
  • Onyx Pharmaceuticals
  • Ortho Biotech
  • OSI Pharmaceuticals
  • Otsuka
  • Oxford University
  • Par Pharmaceutical
  • PDL BioPharma
  • Pfizer
  • PharmaCenter Basel
  • Pharmaceutical Research and Manufacturers of America (PhRMA) [US]
  • Pharmacia
  • Pharmacopeia
  • Pharmacyclics
  • PharmaMar
  • Pharmion
  • Pierre Fabre Pharmaceuticals
  • Pipex
  • Piramal Life Sciences
  • PIramed
  • PolaRx Biopharmaceuticals
  • Poniard Pharmaceuticals
  • Proacta
  • Progenra
  • Prospect Therapeutics
  • Protein Design
  • Proteolix
  • R&R
  • Radient Pharmaceuticals
  • Regeneron
  • Rigel
  • Roche
  • Rockefeller University
  • Roxane Laboratories
  • S*BIO
  • Salk Institute for Biological Studies
  • Sandoz (part of Novartis)
  • Sanofi (sanofi-aventis)
  • Scancell
  • Schering-Plough
  • Scripps Institution of Oceanography
  • Seattle Genetics
  • Semafore
  • Senesco
  • Shire
  • Sigma-Tau
  • Signal Pharmaceuticals
  • Sirton
  • Sloan-Kettering Institute
  • Spectrum Pharmaceuticals
  • Stada Arzneimittel
  • Sun Pharmaceuticals
  • Sunesis
  • Syndax Pharmaceuticals
  • Synta Pharmaceuticals
  • Taiho Pharma
  • Takeda
  • Tapestry Pharmaceuticals
  • TargeGen
  • Telik
  • Teva Pharmaceutical Industries
  • Texas A&M University
  • The NCIC Clinical Trials Group (Canada)
  • Threshold Pharmaceuticals
  • TMRC
  • Toko
  • TopoTarget
  • Tragara
  • Tufts University
  • University of Basel PharmaCenter (PharmaCenter Basel)
  • University of Cambridge
  • University of Kentucky College of Pharmacy
  • University of Michigan
  • University of San Diego
  • US National Cancer Institute
  • US National Comprehensive Cancer Network
  • Vernalis
  • VioQuest
  • Wayne State University
  • WILEX
  • World Health Organization (WHO)
  • Wyeth
  • Xencor
  • XOMA
  • XTL Biopharmaceuticals
  • Yakult Honsha
  • Yeda Research and Development Company
  • YM Biosciences
  • Zelos
  • Zeltia
  • Zenyaku Kogyo
  • Zeria
  • Ziopharm
Back to Top